TABLE IV.
PREDICTIVE ACCURACY (CONCORDANCE INDEX) OF A NOMOGRAM INCLUDING CLINICAL STAGE, BIOPSY GLEASON SUM, AND PRE-TREATMENT PSA (BASE MODEL) AND OF THE BASE MODEL SUPPLEMENTED BY FPSA AND/OR HK2 LEVELS
| Raw data as covariates | Bootstrap corrected | Nomogram probability as covariate | Bootstrap corrected | |
|---|---|---|---|---|
| All 461 patients (n = 461) | ||||
| Base model | 0.819 | 0.813 | 0.806 | 0.806 |
| + fPSA | 0.824 | 0.787 | ||
| + hK2 | 0.820 | 0.807 | ||
| + fPSA & hK2 | 0.827 | 0.818 | 0.802 | 0.797 |
| tPSA ≤ 10 ng/ml (n = 294) | ||||
| Base model | 0.771 | 0.756 | 0.763 | 0.763 |
| + fPSA | 0.782 | 0.739 | ||
| + hK2 | 0.815 | 0.802 | ||
| + fPSA & hK2 | 0.835 | 0.815 | 0.815 | 0.81 |
tPSA, total prostate-specific antigen; fPSA, free prostate-specific antigen; hK2, human glandular kallikrein 2.